Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-related decisions based upon evaluations of reinforcement value and response costs. Furthermore, people with major depression and other disorders often show anergia, psychomotor retardation, fatigue, and alterations in effort-related decision making. Tasks measuring effort-based decision making can be used as animal models of the motivational symptoms of depression, and the present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine. Tetrabenazine induces depressive symptoms in humans, and also preferentially depletes dopamine (DA). Rats were assessed using a concurrent progres...
In humans, psychiatric symptoms such as anergia and psychomotor retardation reflect pathologies in b...
In humans, psychiatric symptoms such as anergia and psychomotor retardation reflect pathologies in b...
Tetrabenazine (TBZ), a vesicular monoamine transporter type 2 (VMAT-2) inhibitor, depletes dopamine ...
Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-r...
Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-r...
Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-r...
Patients with depression, schizophrenia, and other related disorders often show effort-related motiv...
Patients with depression, schizophrenia, and other related disorders often show effort-related motiv...
Patients with depression, schizophrenia, and other related disorders often show effort-related motiv...
Patients with depression, schizophrenia, and other related disorders often show effort-related motiv...
Motivational symptoms related to effort expenditure have been associated with major depression and o...
Motivational symptoms related to effort expenditure have been associated with major depression and o...
The central aim of the present research was to develop animal models that are useful for characteriz...
The central aim of the present research was to develop animal models that are useful for characteriz...
The central aim of the present research was to develop animal models that are useful for characteriz...
In humans, psychiatric symptoms such as anergia and psychomotor retardation reflect pathologies in b...
In humans, psychiatric symptoms such as anergia and psychomotor retardation reflect pathologies in b...
Tetrabenazine (TBZ), a vesicular monoamine transporter type 2 (VMAT-2) inhibitor, depletes dopamine ...
Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-r...
Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-r...
Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-r...
Patients with depression, schizophrenia, and other related disorders often show effort-related motiv...
Patients with depression, schizophrenia, and other related disorders often show effort-related motiv...
Patients with depression, schizophrenia, and other related disorders often show effort-related motiv...
Patients with depression, schizophrenia, and other related disorders often show effort-related motiv...
Motivational symptoms related to effort expenditure have been associated with major depression and o...
Motivational symptoms related to effort expenditure have been associated with major depression and o...
The central aim of the present research was to develop animal models that are useful for characteriz...
The central aim of the present research was to develop animal models that are useful for characteriz...
The central aim of the present research was to develop animal models that are useful for characteriz...
In humans, psychiatric symptoms such as anergia and psychomotor retardation reflect pathologies in b...
In humans, psychiatric symptoms such as anergia and psychomotor retardation reflect pathologies in b...
Tetrabenazine (TBZ), a vesicular monoamine transporter type 2 (VMAT-2) inhibitor, depletes dopamine ...